제넥신
Financials
Valuation Metrics
제넥신's Market Cap is ₩1202B. At end of 2025 it was ₩2134B. Ranked #1112 of 2,436 in KR market (top 46%), #576 of 1,649 on KOSDAQ (top 35%), #131 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 56%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 120.23B KRW | KR#1,112/2,436 Sec#131/234 |
| Revenue | 4.67B KRW | KR#2,351/2,436 Sec#199/234 |
| Net Income | -20.74B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 355.17B KRW | KR#917/2,436 Sec#56/234 |
| Net Assets | 246.76B KRW | KR#808/2,436 Sec#54/234 |
| Employees | 89 | KR#1,716/2,436 Sec#134/234 |
| Value | ||
| P/B | 0.49x | KR#775/2,436 Sec#30/234 |
| P/S | 25.75x | KR#2,344/2,436 Sec#188/234 |
| FCF Yield | -36.86% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -8.40% | KR#1,865/2,436 Sec#142/234 |
| ROA | -5.84% | KR#1,933/2,436 Sec#146/234 |
| Op. Margin | -785.91% | KR#2,384/2,436 Sec#213/234 |
| Revenue Growth | 29.80% | KR#480/2,436 Sec#46/234 |
| Financial Health | ||
| Debt Ratio | 143.93% | KR#1,108/2,436 Sec#125/234 |
| Total Debt | 104.23B KRW | KR#698/2,436 Sec#42/234 |
| FCF | -44.32B KRW | KR#2,070/2,436 Sec#206/234 |
| Cash | 3.85B KRW | KR#2,083/2,436 Sec#192/234 |
| Current Ratio | 0.30x | KR#2,328/2,436 Sec#228/234 |
| Performance | ||
| 1Y Return | -45.79% | KR#1,981/2,436 Sec#180/234 |
| 1M Return | 6.02% | KR#414/2,436 Sec#33/234 |
| From 52W High | -64.75% | KR#1,938/2,436 Sec#165/234 |
| 1Y MDD | -69.08% | KR#1,911/2,436 Sec#162/234 |
| Trading | ||
| Volume | 129,202 shares | KR#789/2,436 Sec#78/234 |
| Foreign Own. | 4.34% | KR#867/2,436 Sec#83/234 |
| Per Share | ||
| EPS | -455 KRW | KR—/2,436 Sec—/234 |
| BPS | 5,050 KRW | KR#1,428/2,436 Sec#105/234 |
Company Info
Established in 1999, the company is a biopharmaceutical enterprise listed on the KOSDAQ market since 2009. Through a 2024 merger with EPD Bio Co., Ltd., it secured the bioPROTAC platform technology EPDeg™. The company is developing various therapeutics, including anticancer immunotherapeutics (GX-I7), utilizing hyFc fusion protein and DNA vaccine manufacturing technologies. It aims for technology transfer through joint development and clinical trials with global pharmaceutical companies to secure future growth engines. Genexine is headquartered in Gangseo-gu, Seoul Metropolitan City.